In this study, anti-CD38 targeted therapy rapidly boosted platelet ... and was associated with mainly low-grade toxic effects. (Funded by the Chinese Academy of Medical Sciences Innovation Fund ...

Building on these data, the preclinical PK model tracked the plasma levels of the CD38-SADA protein. Importantly, the model’s estimated linear clearance of low molecular weight CD38-SADA ...

Building on these data, the preclinical PK model tracked the plasma levels of the CD38-SADA protein. Importantly, the model’s estimated linear clearance of low molecular weight CD38-SADA ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

ISB 2001 was designed to simultaneously target multiple myeloma by binding to the tumor- associated antigens BCMA and CD38, even when expressed at low levels, while engaging T cells to ...

Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggests the anti-CD38 antibody could still “transform treatment” of primary immune ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

The two companies worked together on blood cancer blockbuster Darzalex (daratumumab) – a CD38-targeting antibody which brought in almost $12 billion in sales worldwide last year – but J&J has ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Based on the team’s discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and underlies fibrosis, they created an antibody engineered to selectively ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...